ClinicalTrials.gg

Program

pilabactam sodium

Its studies are mostly in Renal Insufficiency, led by Antabio.

Furthest: phase 1, since May 19, 20233 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Antabio30 open or runningphase 1since May 19, 2023May 19, 2023none ahead

Also a collaborator on its studies: clinartis.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 19, 2023First study: phase 1 study in Healthy VolunteersFirst studyNCT05905913 · 72 enrolled · France
  2. Jul 8, 2024Phase 1 study in Renal InsufficiencyNCT06527677 · 41 enrolled · Germany
  3. Apr 2, 2025Phase 1 study in Pharmacokinetics Study on Healthy Volunteers AdultsNCT06916156 · 26 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06916156Pharmacokinetics Study on Healthy Volunteers Adults · United States1CompletedAug 14, 202526
NCT06527677Renal Insufficiency · Germany1CompletedJul 3, 202541
NCT05905913Healthy Volunteers · France1CompletedJan 5, 202472

How it is read

Names in the registry

  • “ANT3310”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.